Tech Company Financing Transactions
Maxwell Biosciences Funding Round
On 3/10/2022, Maxwell Biosciences announced $10.8 million in Seed investment from DecentraNet, Harvard Business School Angels of Chicago and Joseph Ventures.
Transaction Overview
Company Name
Announced On
3/10/2022
Transaction Type
Venture Equity
Amount
$10,800,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of its innovative platform, recruit and retain talent, pursue clinical trials, and scale up manufacturing capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3809 Juniper Trace 102
Austin, TX 78738
USA
Austin, TX 78738
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Founded in 2016, Maxwell is a preclinical stage biotech targeting viral pandemics. Stanford and NYU scientists invented a new class of broad spectrum anti-infective therapeutics that attack the virus structure directly.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua McClure
Chief Scientific Officer
Kent Kirshenbaum
Co-Founder
Annelise Barron
VP - Operations
Meagan Stone
Browse more venture capital transactions:
Prev: 3/10/2022: in3 venture capital transaction
Next: 3/10/2022: Zeta Surgical venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs